Verdot invests 10 million euros at the Biopôle Clermont-Limagne.

Verdot has announced the construction of its new production plant at the Biopôle Clermont-Limagne in Saint-Beauzire, marking a decisive transformation for the company and the French biopharmaceutical sector. The company specializes in the design, manufacturing, and installation of custom-made low-pressure liquid chromatography equipment used for the purification of a wide range of sensitive biomolecules, such as monoclonal antibodies and active ingredients used in vaccine production or gene therapies.

The construction of the new site, covering an area of approximately 4,200 m², is expected to begin early next year, with completion scheduled for the first quarter of 2026. To meet the growing needs of biopharmaceutical groups, this new facility will increase the company’s production capacity by 150% by 2026. This strategic advancement will enable VERDOT to play a key role in the development of biotherapies in France while strengthening its position in the global market.

Designed to minimize its environmental impact, this new plant will incorporate advanced sustainable production technologies, with the aim of making the site a model of innovation serving both bioprocessing and environmental goals.

With this project, Verdot plans to double its workforce in France, creating 50 to 75 additional jobs, which will reinforce the company’s local presence and contribute to the region’s economic growth.